LSN invites all global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health to apply for the RESI Innovation Challenge. If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

The application deadline for the Innovation Challenge is February 21st

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership. Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

Anton Neschadim, CEO, ImmunoBiochem

“Our first deal was with one of the RESI sponsors and helped us develop fully-human antibody molecules for our lead target, and the subsequent angel-led round allowed us to develop a lead that we showed to be both efficacious and safe in preclinical animal tumor models. “

Kouris Kalligas, Founder & CEO, Therachat

“The RESI Partnering is the best match-making platform I have seen!  I was able to book 16 meetings! And what was really cool is that 10 investors who couldn’t meet with me at RESI gave me their emails through the messaging system, so I was able to contact them afterwards.”

Zohar Beeri, Chairman & CEO, Novotalk

“We had many good meetings on the day of the conference. In addition, we ended up scheduling meetings outside of RESI, either during JPM week or a conference call at a later date with investors who had full schedules. We are following up with quite a few investors, including an investor that I met by chance during the cocktail hour…”

David Narrow, CEO, Sonavex

“RESI is a really efficient way to have a lot of vetted meetings with investors. I have had many fruitful discussions with investors at the different RESIs I have attended, which is why I continue to attend…We actually met one of the key investors in our Series A round through RESI—Fusion Fund—and we are still in discussions with several other investors. “

Steven ten Holder, COO, Acorn Biolabs

“I think I must have spoken to at least 30 or 40 investors at the poster… I can think of 3 investors in particular who are very interested in our company and we are already following up with them.”